Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
22.59
+0.05 (0.24%)
Sep 28, 2026, 3:15 PM EDT - Market open
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Collegium Pharmaceutical stock has a consensus rating of "Buy" and an average price target of $49. The average 1-year stock price forecast is 116.96% higher than the current stock price, while the lowest is $43 (+90.39%) and the highest is $60 (+165.66%).
Price Target: $49 (+116.96%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Collegium Pharmaceutical stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 5 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Initiates $50 | Buy | Initiates | $50 | +121.39% | Sep 23, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $60 | Buy | Maintains | $60 | +165.66% | Sep 21, 2026 |
| Leerink Partners | Leerink Partners | Buy Initiates $45 | Buy | Initiates | $45 | +99.25% | Sep 9, 2026 |
| Truist Financial No rating | Truist Financial | Buy Initiates $58 → $49 | Buy | Initiates | $58 → $49 | +116.96% | Sep 9, 2026 |
| Barclays | Barclays | Buy Reiterates $56 → $48 | Buy | Reiterates | $56 → $48 | +112.53% | Aug 19, 2026 |
Financial Forecast
Revenue This Year
837.13M
from 780.57M
Increased by 7.25%
Revenue Next Year
850.12M
from 837.13M
Increased by 1.55%
EPS This Year
7.36
from 7.42
Decreased by -0.75%
EPS Next Year
6.68
from 7.36
Decreased by -9.25%
EPS and Forward PE are based on non-GAAP adjusted numbers.